1-3 of 3
Mario Sznol
Close
Sort by
Journal Articles

Phase I Study of Triapine® and Cytarabine (ara-C) in Patients with Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndrome (MDS).

Karen W.L. Yee, MD, Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD, Deborah Thomas, MD, Stefan Faderl, MD, Ivan King, PhD, Susan M. O’Brien, MD, Mario Sznol, MD, Francis J. Giles, MD
Journal: Blood
Blood (2005) 106 (11): 4925.
https://doi.org/10.1182/blood.V106.11.4925.4925
Published: 2005
Journal Articles

A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma

Clinical Trials & Observations
John E. Janik, Langdon L. Miller, Edward L. Korn, Diane Stevens, Brendan D. Curti, John W. Smith, II, Mario Sznol, Kevin C. Conlon, William Sharfman, Walter J. Urba, Barry L. Gause, Dan L. Longo
Journal: Blood
Blood (2001) 97 (7): 1942–1946.
https://doi.org/10.1182/blood.V97.7.1942
Published: 2001
Journal Articles

Abrogation of the Hematological and Biological Activities of the Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein PIXY321 by Neutralizing Anti-PIXY321 Antibodies in Cancer Patients Receiving High-Dose Carboplatin

Langdon L. Miller, Edward L. Korn, Diane S. Stevens, John E. Janik, Barry L. Gause, William C. Kopp, Jon T. Holmlund, Brendan D. Curti, Mario Sznol, John W. Smith, II, Walter J. Urba, Sarah E. Donegan, Thelma M. Watson, Dan L. Longo
Journal: Blood
Blood (1999) 93 (10): 3250–3258.
https://doi.org/10.1182/blood.V93.10.3250.410k35_3250_3258
Published: 1999